Health-care products maker Johnson & Johnson won US approval to sell a new HIV drug called Intelence for patients with resistance to other therapies, US officials said on Friday. The drug, also known as TMC125 or etravirine, is a new member of the family of AIDS-fighting drugs called non-nucleoside reverse transcriptase inhibitors (NNRTI).
More than two dozen drugs are approved for fighting the deadly HIV virus. Patients need new options because HIV can mutate to resist existing treatments.
Comments
Comments are closed.